Selecta Biosciences, Inc. – NASDAQ:SELB
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Selecta Biosciences stock price monthly change
-33.45%
month
Selecta Biosciences stock price quarterly change
-36.35%
quarter
Selecta Biosciences stock price yearly change
-44.12%
year
Selecta Biosciences key metrics
Market Cap | 135.20M |
Enterprise value | 94.85M |
P/E | 13.1 |
EV/Sales | 1.00 |
EV/EBITDA | 2.37 |
Price/Sales | 2.01 |
Price/Book | 2.02 |
PEG ratio | 0.06 |
EPS | -0.27 |
Revenue | 34.53M |
EBITDA | -57.28M |
Income | -40.24M |
Revenue Q/Q | -68.36% |
Revenue Y/Y | -72.13% |
Profit margin | 37.64% |
Oper. margin | 15.47% |
Gross margin | 41.79% |
EBIT margin | 15.47% |
EBITDA margin | -165.88% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSelecta Biosciences stock price history
Selecta Biosciences stock forecast
Selecta Biosciences financial statements
| Dec 2022 | 16.79M | 5.89M | 35.09% |
|---|---|---|---|
| Mar 2023 | 5.93M | -25.75M | -433.7% |
| Jun 2023 | 5.24M | -11.38M | -216.94% |
| Sep 2023 | 6.55M | -9.00M | -137.41% |
| 2025 | 41.68M | -16.86M | -40.46% |
|---|
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 155693000 | 81.11M | 52.1% |
|---|---|---|---|
| Jun 2023 | 139506000 | 74.05M | 53.09% |
| Sep 2023 | 106034000 | 45.70M | 43.1% |
| Dec 2023 | 305050000 | 444.68M | 145.77% |
| Dec 2022 | -11.84M | 5.48M | 0 |
|---|---|---|---|
| Mar 2023 | -8.76M | 28.12M | 149K |
| Jun 2023 | -9.89M | -12K | -2.58M |
| Sep 2023 | -9.21M | 0 | -24.78M |
Selecta Biosciences alternative data
| Aug 2023 | 64 |
|---|---|
| Sep 2023 | 64 |
| Oct 2023 | 64 |
| Nov 2023 | 64 |
| Dec 2023 | 64 |
| Jan 2024 | 64 |
| Feb 2024 | 64 |
| Mar 2024 | 64 |
| Apr 2024 | 64 |
| May 2024 | 64 |
| Jun 2024 | 64 |
| Jul 2024 | 64 |
Selecta Biosciences other data
47.71%
-0.80%
of SELB is owned by hedge funds
93
-10
54.55M
-1.31M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 0 | 4522 |
| Jan 2023 | 0 | 72282 |
| Sep 2023 | 0 | 3637 |
| Nov 2023 | 619 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KALAYOGLU MURAT director, 10 percent owner: | Series A Non-Voting Convertible Preferred Stock | 619 | N/A | N/A | ||
Sale | BRUNN CARSTEN director, officer.. | Common Stock | 2,932 | $1.06 | $3,108 | ||
Sale | TRABER PETER G officer: Chief Me.. | Common Stock | 705 | $1.06 | $747 | ||
Sale | JOHNSTON LLOYD P. officer: Chief Operations Officer | Common Stock | 20 | $1.11 | $22 | ||
Sale | JOHNSTON LLOYD P. officer: Chief Operations Officer | Common Stock | 3,372 | $1.13 | $3,807 | ||
Sale | BRUNN CARSTEN officer: Presiden.. | Common Stock | 77 | $1.12 | $86 | ||
Sale | BRUNN CARSTEN officer: Presiden.. | Common Stock | 13,396 | $1.13 | $15,124 | ||
Sale | KISHIMOTO TAKASHI KEI officer: Chief Scientific Officer | Common Stock | 3,372 | $1.13 | $3,807 | ||
Sale | KISHIMOTO TAKASHI KEI officer: Chief Scientific Officer | Common Stock | 20 | $1.11 | $22 | ||
Sale | TRABER PETER G officer: Chief Me.. | Common Stock | 3,445 | $1.13 | $3,889 |
| Patent |
|---|
Application Filling date: 4 Nov 2021 Issue date: 5 May 2022 |
Grant Utility: Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity Filling date: 11 Jun 2019 Issue date: 12 Apr 2022 |
Application METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE Filling date: 24 Mar 2021 Issue date: 10 Mar 2022 |
Grant Utility: Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses Filling date: 6 Aug 2018 Issue date: 1 Feb 2022 |
Application Filling date: 11 Mar 2021 Issue date: 7 Oct 2021 |
Application Filling date: 26 Feb 2021 Issue date: 23 Sep 2021 |
Application Filling date: 6 Nov 2020 Issue date: 24 Jun 2021 |
Application Filling date: 21 Oct 2020 Issue date: 27 May 2021 |
Application Filling date: 4 Jun 2020 Issue date: 24 Dec 2020 |
Application Filling date: 28 May 2020 Issue date: 17 Dec 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2023 4 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 2 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 5 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 6 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Carsten Brunn (1971) Chief Executive Officer, Pres & Director | $917,020 |
| Dr. Peter G. Traber M.D. (1955) Chief Medical Officer | $587,600 |
Selecta: Despite Challenges, Dissolve Topline Data Could Move The Stock
Why Horizon Therapeutics Is One Of The Best Investments In Biotech Today
Selecta: ImmTOR Could Change Autoimmune Disorder Treatment Landscape
MDA Breakout Stocks Week 32 - August 2022: Short-Term Picks To Give You An Edge
Greenblatt's Magic Formula For Beating The Market
Selecta Biosciences Has Multiple Shots On Goal
Selecta: ImmTOR Promises A Therapeutic Revolution, But SEL-212 May Dash Hopes
-
When is Selecta Biosciences's next earnings date?
Unfortunately, Selecta Biosciences's (SELB) next earnings date is currently unknown.
-
Does Selecta Biosciences pay dividends?
No, Selecta Biosciences does not pay dividends.
-
How much money does Selecta Biosciences make?
Selecta Biosciences has a market capitalization of 135.20M.
-
What is Selecta Biosciences's stock symbol?
Selecta Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "SELB".
-
What is Selecta Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Selecta Biosciences?
Shares of Selecta Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Selecta Biosciences's key executives?
Selecta Biosciences's management team includes the following people:
- Dr. Carsten Brunn Chief Executive Officer, Pres & Director(age: 54, pay: $917,020)
- Dr. Peter G. Traber M.D. Chief Medical Officer(age: 70, pay: $587,600)
-
How many employees does Selecta Biosciences have?
As Jul 2024, Selecta Biosciences employs 64 workers.
-
When Selecta Biosciences went public?
Selecta Biosciences, Inc. is publicly traded company for more then 9 years since IPO on 22 Jun 2016.
-
What is Selecta Biosciences's official website?
The official website for Selecta Biosciences is selectabio.com.
-
Where are Selecta Biosciences's headquarters?
Selecta Biosciences is headquartered at 65 Grove Street, Watertown, MA.
-
How can i contact Selecta Biosciences?
Selecta Biosciences's mailing address is 65 Grove Street, Watertown, MA and company can be reached via phone at +61 79231400.
Selecta Biosciences company profile:
Selecta Biosciences, Inc.
selectabio.comExchange:
NASDAQ
Full time employees:
64
Industry:
Biotechnology
Sector:
Healthcare
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising SEL-313, a product candidate in preclinical stage to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to evaluate the appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and products for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat primary biliary cholangitis and other autoimmune diseases. The company has license and collaboration agreements with Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum; Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Ginkgo Bioworks Holdings, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
65 Grove Street
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001453687
ISIN: US8162121045
CUSIP: 816212104
